Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. - Wikidata - awgldk - TriplyDB

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

http://www.wikidata.org/entity/Q33367113

about

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Clearance kinetics and external dosimetry of 131I-labeled murine and humanized monoclonal antibody A33 in patients with colon cancer: radiation safety implications.Quantitative Shotgun Proteomics Unveils Candidate Novel Esophageal Adenocarcinoma (EAC)-specific Proteins.Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.(124)I-huA33 antibody PET of colorectal cancer.PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines.Cell surface markers in colorectal cancer prognosis.The new golden era for radioimmunotherapy: not just for lymphomas anymore.General overview of radioimmunotherapy of solid tumors.Antibody-mediated delivery of therapeutics for cancer therapy.Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma.A33 antigen displays persistent surface expression.Targeted nanoparticles for colorectal cancer.Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma.Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer

P2860

Q33301860-6A8EC712-67EA-4196-A411-DCDA0E77B40F Q33709465-85E9D25F-CD6C-4233-A18F-4F4AC57AB693 Q33771039-FE5FFD7A-FA3A-4F28-93B7-F05AB9252982 Q33803210-671F456E-6A12-483C-ADE7-51FF811D81A5 Q35640393-E87C4FAF-1A84-4BF7-9D5B-1E35E4D2B4BE Q36088136-5DAA97A7-B736-40DE-A5CB-598C5912412C Q36088144-21C0F03B-858D-4C87-863D-3A0A3CDD0ED5 Q36911658-F374E519-4108-4220-BB5C-650CF4A2E5C8 Q37002044-7211E7DC-75AD-4DAF-AFBB-66EA21C8CF0C Q37468620-731DCD3D-2669-468E-A0E6-94D5195D08CD Q37845669-583F323A-9EA3-4869-B932-2CED3354B613 Q38072815-9926269C-34ED-4406-BB65-5C200AA2A94F Q38103579-FA7E9EB7-53C0-42A5-9B36-89E389745A7F Q38665425-8F91F671-BFA1-4F0E-9C35-78ADD8B85291 Q38932565-5CF818CC-210C-4288-AD56-FC8B3CCD857C Q39543140-D6921631-68A4-448D-957E-5FB00CE5DE11 Q42365964-F0197913-62EA-4A23-BAF6-5BD6774FFE3F Q47926790-1FF2BB0B-90AC-49E9-B2B8-ABB7297383DA Q52877939-EEB7021D-69AD-4D47-BA5F-5524E0165B63 Q53248440-C2DA2766-2C07-479E-8D1B-5A950A59DCDE Q58924867-E32C3E5A-00DB-481C-A434-5E5E6FD36069

P2860

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

http://www.wikidata.org/entity/Q33367113

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

@ast

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

@en

type

label

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

@ast

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

@en

prefLabel

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

@ast

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

@en

P1433

Q33367113-0CE451FC-D445-4952-94F9-CD05EE71358C

P1476

Q33367113-4B47869E-D0CA-4487-8FF0-0EA57FDA3746

P2093

Q33367113-16CD1349-3862-485A-9EE9-05DCD64827A4

Q33367113-1B365E8E-7F5C-4466-9ACC-5AC92C42902D

Q33367113-1F479875-A123-4CEF-BAC8-B9639893DBFC

Q33367113-36F52E59-21C8-4DA2-871C-AA32149AB228

Q33367113-4C0246A9-7CAF-4DCD-A3FD-0EBB9400D29B

Q33367113-4D2F3C29-2501-4D52-98F4-E35A61D105D0

Q33367113-66F01AD5-D55E-42AC-978F-651D0B67D50D

Q33367113-8315C1A9-4A98-4BA8-8BEE-4D094A55B768

Q33367113-8CB5C4DD-DDA9-419F-A018-914FB0154BAC

Q33367113-8E1766DD-0365-4DC7-9FB3-1BA311DD2A72

P304

Q33367113-01C4A81A-568E-42F5-8EFB-99C15EA754B1

P31

Q33367113-4FB3F2BB-0ECF-4EB6-ACC3-5D45B9C8933D

P356

Q33367113-823846EB-A3E5-4681-AEEA-6354F89E12EB

P407

Q33367113-6FD114C7-4BF0-4FA1-ADFD-997719AA558A

P433

Q33367113-2631BFEC-052E-48EB-BE1A-A092CE48D104

P478

Q33367113-A7268223-6440-443F-8B5C-CC76FE8EDFDA

P50

Q33367113-63F42467-94BC-4811-92E9-6CDDF933F113

P577

Q33367113-16AC7FCB-9214-421C-A149-881F6CFA78F5

P698

Q33367113-E0E48896-4429-45E5-8B6F-67E4E369D4C4

P921

Q33367113-A3777B55-D27F-43F7-A8A1-04BAA17490EB

P356

1078-0432.CCR-04-2330

P1433

Clinical Cancer Research

P1476

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

@en

P2093

Andrew M Scott

http://www.w3.org/2001/XMLSchema#string

Angela J Mountain

http://www.w3.org/2001/XMLSchema#string

Antony W Burgess

http://www.w3.org/2001/XMLSchema#string

Aurora Poon

http://www.w3.org/2001/XMLSchema#string

Bridget Chappell

http://www.w3.org/2001/XMLSchema#string

Eric W Hoffman

http://www.w3.org/2001/XMLSchema#string

Fiona E Smyth

http://www.w3.org/2001/XMLSchema#string

Fook Thean Lee

http://www.w3.org/2001/XMLSchema#string

Geoffrey Chong

http://www.w3.org/2001/XMLSchema#string

Graeme J O'keefe

http://www.w3.org/2001/XMLSchema#string

P304

4818-4826

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-04-2330

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Anthony T. Papenfuss

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16000579

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial